NCT05695352View on ClinicalTrials.gov

Oral Levonorgestrel Plus Meloxicam, IG-002 Delays Ovulation in Normal Menstruating Women by Seven Days

PHASE2RecruitingINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

June 28, 2022

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions
Pregnancy Prevention
Interventions
DRUG

Levonorgestrel 1.5mg

oral synthetic progesterone agonist

DRUG

Meloxicam 15 mg

Non steroidal autoinflammatory drug inhibiting both Cyclooxygenase -1 and -2 enzymes

OTHER

Placebo

Each tablet contains Calcium Carbonate 1000 mg

Trial Locations (1)

27713

RECRUITING

Carolina Women's Research and Wellness Center, Raleigh

All Listed Sponsors
collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

lead

InnovaGyn, Inc.

OTHER